CYD-1-79
CYD-1-79 is a selective positive allosteric modulator of 5-HT2C receptor. CYD-1-79 potentiates 5-HT-evoked intracellular calcium release via a topographically distinct allosteric site. CYD-1-79 shows significant inhibition of binding at dopamine D3 receptor, DAT, and α2A/α2B adrenergic receptors. CYD-1-79 modulates 5-HT2C receptor-mediated spontaneous ambulation in rodents and synergizes with a low dose of a 5-HT2C receptor agonist. CYD-1-79 attenuates relapse vulnerability of psychoactive substance in a rodent self-administration model. CYD-1-79 can be used for the research of neurological disease.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 2220235-94-7
- Fòrmula: C20H40N2O3
- Peso molecular:356.54
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Ver todos los productos específicos de isoformas 5-HT Receptor
MoreVer todos los productos específicos de isoformas Dopamine Receptor
MoreVer todos los productos específicos de isoformas Adrenergic Receptor
MoreVer todos los productos específicos de isoformas Calcium Channel
More
Actividad biológica
|
5-HT2C Receptor |
D3 Receptor |
Alpha-2A adrenergic receptor |
Alpha-2B adrenergic receptor |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | Emax |
123.2 %
Compound: 16
|
Positive allosteric modulation of human 5-HT2CR expressed in CHO cells assessed as 5-HT-induced intracellular calcium release at 1 nM preincubated for 15 mins followed by 5-HT addition by calcium-4 dye based FLIPR assay (Rvb = 100%)
Positive allosteric modulation of human 5-HT2CR expressed in CHO cells assessed as 5-HT-induced intracellular calcium release at 1 nM preincubated for 15 mins followed by 5-HT addition by calcium-4 dye based FLIPR assay (Rvb = 100%)
|
[PMID: 29620897] |
| CHO | Emax |
123.2 %
Compound: 3; CYD-1-79
|
Positive allosteric modulation of human 5HT2CR expressed in CHO cells assessed as increase in 5-HT induced intracellular calcium release at 1 nM preincubated for 15 mins followed by 5-HT addition and measured at 1 secs interval for 360 secs by calcium 4 d
Positive allosteric modulation of human 5HT2CR expressed in CHO cells assessed as increase in 5-HT induced intracellular calcium release at 1 nM preincubated for 15 mins followed by 5-HT addition and measured at 1 secs interval for 360 secs by calcium 4 d
|
[PMID: 32567857] |
CYD-1-79 (Compound 16) (1 pM-1 μM; 15 min) promotes an upward shift of 5-HT-evoked Cai2+ release at multiple
concentrations without a leftward shift[1].
CYD-1-79 (1 pM-1 μM; 15 min) does not modulate 5-HT2A receptor-mediated intracellular calcium release in h5-HT2A R-CHO cells, demonstrating subtype selectivity for 5-HT2C receptors[1].
CYD-1-79 (10 μM) does not significantly bind to orthosteric sites of 5-HT receptor subtypes, including 5-HT2C, but shows significant inhibition of binding at dopamine D3 receptor, DAT, and α2A/α2B adrenergic receptors[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
CYD-1-79 (5 mg/kg; i.p.; single dose) allosterically potentiates the locomotor-suppressant effects of the 5-HT2C agonist WAY163909 (HY-15401) in male Sprague-Dawley rats, an effect mediated by 5-HT2C receptor activation[1].
CYD-1-79 (0.125-1 mg/kg; i.p.; single dose) partially substitutes for the discriminative stimulus effects of the 5-HT2C agonist WAY163909 when administered alone, but synergizes with a low dose of WAY163909 (0.5 mg/kg) to produce full substitution for its discriminative stimulus effects in trained male Sprague-Dawley rats[1].
CYD-1-79 (compound 16) (1 mg/kg; i.p.; single dose) significantly suppresses psychoactive substance cue reactivity in male Sprague-Dawley rats trained to self-administer psychoactive substance[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (male, 225-325 g)[1]
-
Dosage:0.5 mg/kg; 1 mg/kg; 5 mg/kg
-
Administration:i.p.; single dose
-
Result:Significantly reduced mean total ambulations and mean total vertical activity (±SEM) compared to saline at 5 mg/kg (p < 0.05).
Did not produce statistically significant changes in ambulations or vertical activity relative to saline at 0.5 mg/kg and 1 mg/kg.
-
Animal Model:Sprague-Dawley (male, 250-275 g, trained to self-administer psychoactive substance)[1]
-
Dosage:1 mg/kg
-
Administration:i.p.; single dose
-
Result:Significantly reduced presses on the previously active lever during the 60-minute cue-reinforced component compared to vehicle (p < 0.05, with significant differences observed at multiple 5-minute time points).
Did not significantly alter inactive lever presses relative to vehicle.
Chemical Information
-
No. CAS 2220235-94-7
-
Peso molecular 356.54
-
Fòrmula C20H40N2O3
-
SMILES
O=C([C@H]1NCC[C@@H](CCCCCCCCCCC)C1)NCC(O)CO
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
- CYD-1-79
- 2220235-94-7
- 5-HT Receptor
- Dopamine Receptor
- Dopamine Transporter
- Adrenergic Receptor
- Calcium Channel
- 5-HT2A receptor
- h5-HT2A R-CHO cells
- dopamine D3 receptor
- DAT
- α2A adrenergic receptors
- h5-HT2C R-CHO cells
- 5-HT2C receptor
- intracellular calcium release
- α2B adrenergic receptors
- cocaine use disorder
- Inhibitor
- inhibitor
- inhibit